Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2019-09-09 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a press release dated September 9, 2019, announcing that the Israeli Patent Authority has allowed a patent application covering the company's ALLOCETRATM immunotherapy. This announcement pertains to intellectual property protection and is not a comprehensive financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate update regarding intellectual property, which does not fit neatly into the primary financial filing categories. Since it is a specific announcement about a legal/IP matter, it is best classified as a Regulatory Filing (RNS) as a general announcement, or potentially related to Intellectual Property (IP) if that category were broader. Given the available options, and since it is a specific announcement that doesn't match the defined categories like DIV, ER, or 10-K, RNS (Regulatory Filings - general regulatory announcements/fallback) is the most appropriate general classification for this type of corporate news release, although 'IP' (Intellectual Property) might seem relevant, it is not explicitly defined as a category for patent announcements. However, looking closely at the definitions, there is no specific 'Patent' or 'IP' category. Therefore, RNS serves as the best fit for a non-financial, non-management, non-meeting specific corporate announcement.
2019-09-09 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is very short (1797 characters) and explicitly states, 'Attached hereto is a report on *tent_isa.pdf*'. This structure—a brief filing announcing the availability of an attached or linked report—fits the definition of a Report Publication Announcement (RPA). It is not the full report itself (like 10-K or IR). The filing is made to the Israel Securities Authority and Tel Aviv Stock Exchange, indicating a regulatory context, but the specific action described is the publication announcement.
2019-09-09 English
Immediate Report
Investor Presentation Classification · 1% confidence The document is a press release announcing that Enlivex Therapeutics management will be making a corporate presentation at the '21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co.' on September 9th, 2019. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing about results (ER). It is an announcement about participation in an investor-focused event where a presentation will be given. This aligns best with the Investor Presentation (IP) category, as the core purpose is to present company information to investors at a conference, even if the document itself is the announcement of that presentation.
2019-09-04 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is very short (1832 characters) and explicitly states, "Attached hereto is a report on *pressrelease090419_enlivextherapeutics_isa.pdf*". This structure—a brief filing announcing the attachment or publication of a separate, detailed report—triggers the 'MENU VS MEAL' rule. It is not the full report itself (like 10-K or IR). Furthermore, it is filed under 'Immediate Report' with the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE), suggesting a general regulatory disclosure. Since it is an announcement of a report/press release and doesn't fit specific categories like DIV, DIRS, or ER, the most appropriate classification is Report Publication Announcement (RPA) or the general fallback Regulatory Filings (RNS). Given the explicit mention of attaching a PDF report, RPA is more precise than RNS.
2019-09-04 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," filed on Form 6-K for August 2019. Form 6-K filings are used by foreign private issuers to report material information to the SEC, often mirroring the function of a current report (8-K) in the US system. The content is a press release announcing positive safety data from a clinical trial (severe sepsis). Since Form 6-K is a general reporting mechanism for foreign private issuers and the content is a material event announcement (clinical trial update), it does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or IR (Interim Report). The most appropriate general category for a material, non-standard regulatory filing that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as 6-K is a mandatory SEC filing type for this issuer type, and the content is a material update. However, looking closely at the provided definitions, 'RNS' is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' While Form 6-K is a specific SEC form, its function here is to disseminate material news, which aligns with the spirit of a regulatory announcement. Given the options, RNS is the best fit for a Form 6-K that isn't an annual report or a specific financial disclosure like earnings or dividends.
2019-08-19 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document explicitly mentions 'Immediate Report' under 'Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000' and states 'Attached hereto is a report on *6K* *PR19082019_magna_isa.pdf*'. The presence of '6K' (likely referring to an SEC Form 6-K, which is an immediate report for foreign private issuers) and the structure strongly suggest this is an announcement about the filing of an external report, rather than the full report itself. Given the short length (1778 chars) and the nature of announcing an attached document, this fits the criteria for a Report Publication Announcement (RPA).
2019-08-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.